ArticleeLife2020
Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
0.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Long-Term Thyroid Complications Post-COVID-19: A Systematic Review.Microorganisms · 2026Review
- Extensive Immunological and Inflammatory Perturbation Underpins the Respiratory Sequelae of Postacute COVID-19.Open forum infectious diseases · 2026Article
- Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.Computational and structural biotechnology journal · 2025Review
- Antimicrobial, antibiofilm, and antiviral investigations using egyptian phoenix dactylifera L. pits extract.AMB Express · 2024Article
- Coronavirus disease 2019 (COVID-19)-associated brain abscesses caused by Pseudomonas aeruginosa and Aspergillus fumigatus: two case and a review of the literature.Journal of medical case reports · 2023Review
- Article
- Article
- Role of T cells in severe COVID-19 disease, protection, and long term immunity.Immunogenetics · 2023Review
- Hematological alterations associated with long COVID-19.Frontiers in physiology · 2023Review
- Incidence, Outcomes and Risk Factors of Recurrent Ventilator Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study.Journal of clinical medicine · 2022Article
- Bioactivity and Pharmacological Potential of Date Palm (Phoenix dactylifera L.) Against Pandemic COVID-19: a Comprehensive Review.Applied biochemistry and biotechnology · 2022Review
- Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infectionImmunity and inflammaion in post-acute sequelae of SARS-CoV-2 infection.Current opinion in immunology · 2022Review
- Post COVID syndrome: A novel challenge and threat to international health.Nepal journal of epidemiology · 2022Article
- Emerging role of bystander T cell activation in autoimmune diseases.BMB reports · 2022Review
- Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.Nature immunology · 2022Article
- Long COVID: a narrative review of the clinical aftermaths of COVID-19 with a focus on the putative pathophysiology and aspects of physical activity.Oxford open immunology · 2022Review
- Prevention and treatment of ventilator-associated pneumonia in COVID-19.Frontiers in pharmacology · 2022Review
- Long COVID, a comprehensive systematic scoping review.Infection · 2021Article
- Evolving phenotypes of non-hospitalized patients that indicate long COVID.BMC medicine · 2021Article
- A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol againstRSC medicinal chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 1 country.
Michaela Gregorova *School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.ORCID 0000-0003-1605-0558
Daniel Morse *School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Tarcisio Brignoli *School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Joseph SteventonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Fergus HamiltonNorth Bristol NHS Trust, Bristol, United Kingdom.
Mahableshwar AlburNorth Bristol NHS Trust, Bristol, United Kingdom.ORCID 0000-0001-9792-7280
David ArnoldNorth Bristol NHS Trust, Bristol, United Kingdom.ORCID 0000-0003-3158-7740
Matthew ThomasNorth Bristol NHS Trust, Bristol, United Kingdom.
Alice HallidaySchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Holly BaumSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Christopher RiceSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Matthew B AvisonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Andrew D DavidsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-1136-4008
Marianna SantopaoloSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Elizabeth OliverSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Anu GoenkaSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Adam FinnSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Linda WooldridgeBristol Veterinary School in the Faculty of Health Sciences, Bristol, United Kingdom.
Borko AmulicSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Rosemary J BoytonDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Daniel M AltmannDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
David K ButlerDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Claire McMurrayInstitute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Joanna StocktonInstitute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Sam NichollsInstitute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Charles CooperInstitute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Nicholas LomanInstitute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Michael J CoxLung Division, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Laura Rivino *School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.ORCID 0000-0001-6213-9794
Ruth C Massey *School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-8154-4039
University of Bristol · GBUniversity of Birmingham · GBNorth Bristol NHS Trust · GBImperial College London · GBRoyal Brompton & Harefield NHS Foundation Trust · GBAt Bristol · GB
Funding
Biotechnology and Biological Sciences Research Council BB/H005439/1Department of Health DRF-2018-11-ST2-065Medical Research Council MR/J014370/1Medical Research Council MR/M501621/1Medical Research Council MR/R02149X/1Medical Research Council MR/R02622X/1Medical Research Council MR/S019553/1Medical Research Council MR/V027506/1Wellcome Trust 212258/Z/18/Z
Abstract
Here, we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by
Indexed as
Lymphocyte ActivationSARS-CoV-2Anti-Bacterial AgentsCOVID-19Drug Resistance, Multiple, BacterialHumansLungMaleMeropenemMetagenomicsMiddle AgedPiperacillin, Tazobactam Drug CombinationPneumonia, Ventilator-AssociatedPseudomonas aeruginosaPseudomonas InfectionsRecurrenceAnti-Bacterial AgentsMeropenemPiperacillin, Tazobactam Drug Combinationhumaninfectious diseasemetagenomicsmicrobiologyPseudomonas aeruginosaSARS-CoV-2t-cells activation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.